Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is typically associated with extensive and progressive fibrosis, and is fatal and has limited treatment options. Characteristically IPF patients display large lymphocyte aggregates composed of CD3 + T cells and CD20 + B cells within the lung tissue that are located near sites of active fibrosis. In addition, IPF patients can have autoantibodies to a range of host antigens, suggesting a breakdown in immunological tolerance. In this review, we examine the role of T and B cells in IPF pathogenesis and discuss how loss of self-tolerance to lung-specific proteins could exacerbate disease progression in IPF. We discuss what these results mean in terms of future prospects for immunotherapy of IPF.
INTRODUCTION
Interstitial lung diseases (ILDs) are a heterogeneous group of lung disorders. There are many types of ILDs, which recently have been reclassified into three broad categories as follows: (1) chronic fibrosing interstitial pneumonia (including idiopathic pulmonary fibrosis (IPF)), (2) Smoking-related interstitial pneumonia (respiratory bronchiolitis-ILD and desquamative interstitial pneumonia) and (3) acute/sub-acute interstitial pneumonia (including cryptogenic organising pneumonia and acute interstitial pneumonia). These groupings are based on clinical, radiological and pathological findings. 1 IPF is a chronic and fatal disease characterised by excessive extracellular matrix protein deposition and a subsequent, and progressive decline in lung function. It has no known cause and there are limited treatment options that have minimal impact on survival times for IPF patients. 2 The incidence of IPF is increasing and is currently reported to be about 20 per 100 000 in the USA and Europe. 3, 4 The pathogenesis of IPF remains poorly understood, but it has been proposed that ongoing or repetitive injury to alveolar type II epithelial cells results in increased apoptosis and in the induction of chronic inflammation with monocytic and lymphocytic infiltration. 5 The chronic nature of this response leads to fibroblast proliferation and myofibroblast differentiation, and the excessive deposition and accumulation of extracellular matrix proteins, predominately type I collagen, within the lung interstitium. 6 There is a growing appreciation for the role of adaptive immune responses in the initiation and/or progression of a range of fibrotic diseases. In IPF patients, the presence of lymphoid aggregates in the lung tissue together with autoantibodies present in the serum, suggest that the immune system is likely to play a role either in initiation or progression of the disease. For example, the loss of self-tolerance in autoreactive T and B cells specific to antigens derived from damaged or dying lung epithelial cells may drive immune pathology in IPF. In this review, we will provide an overview of how dysregulation of the adaptive immune response drives chronic inflammation and fibrosis that are hallmarks of IPF.
CHARACTERISATION OF LYMPHOCYTE RESPONSES IN IPF
IPF has an unknown aetiology but it is characterised by an inflammatory cell infiltrate that includes neutrophils and mononuclear cells. 7, 8 In addition, eosinophils and increased numbers of CD4 + T cells together with raised antibody levels have been reported in the bronchoalveolar lavage of patients with pulmonary fibrosis. [8] [9] [10] Although these findings suggest a role for innate and adaptive immunity in the disease process until recently, there have been no clear links made between antigens that may trigger the immune response and disease pathogenesis. The predominance of T cells in lung tissue and the bronchoalveolar lavage fluid of patients with IPF suggested a role for cell-mediated immune responses in the disease process. However, at the time biomarkers of T-cell subsets did not correlate with disease activity or prognosis. 11 Lymphocyte aggregates in the IPF lung consist of CD3 + T lymphocytes and mature dendritic cells and are generally proximate to fibroblastic foci. 9, 12, 13 A subset of these aggregates also contain CD20 + B cells, which localise in cohesive focal clusters within the centre of the aggregate resulting in an organised appearance 9, 12, 14 (Figure 1 ). These tertiary lymphoid structures (TLSs) have been classified as ectopic lymphoid structures and contain non-proliferating and non-apoptotic mature CD45RO + T and B cells evidenced by Ki67 and cleaved caspase 3 staining 9,12 ( Figure 2 ). This is a unique feature of IPF, as pulmonary TLSs present in other diseases such as chronic obstructive pulmonary disease and idiopathic pulmonary arterial hypertension are non-proliferative. 9, 12 Furthermore, TLSs contain mature supporting dendritic cells and large endothelial cells resembling high endothelial venules reminiscent of lymph node organisation. 12 These inducible TLSs enable B cells to proliferate and differentiate in response to antigen independently of secondary lymphoid organs. 12 However, the fact that these TLSs, evident in IPF lung tissue, contain non-proliferating and non-apoptotic T and B cells suggests another mechanism is occurring. Despite this, the fact that these TLS are a histological feature of IPF and absent in the healthy lung suggests that they are an important feature of the disease pathogenesis.
In an attempt to further characterise the properties of the lymphocyte infiltrate in IPF patients Herazo-Maya et al. 15 examined gene expression arrays using DNA prepared from peripheral blood mononuclear cells and they revealed a unique genetic signature that correlated with disease progression in IPF patients. The genetic signature comprised four genes that displayed decreased expression levels in IPF patients and these included Cd28, Icos, Itk and Lck, and these markers were confirmed at both the RNA and protein level. 15 Furthermore, the signature correlated with a two-to four-fold increased risk of patients dying of IPF or having a lung transplant. 15 Other genes that were downregulated in IPF patients were associated with the T-cell antigen receptor complex such as CD3ε, CD3δ, CD3γ suggesting a general downregulation of T-cell receptors (TCRs) and some of these were confirmed by flow cytometry. This finding was supported independently by Gilani et al. 16 using peripheral blood CD4 + T cells, which also showed decreased CD28 levels on CD4 + T cells of IPF patients and confirmed that this phenotype correlated with poor survival. These findings of modulation of CD28 expression and predisposition to IPF disease progression in patients are in stark contrast to results obtained with Cd28 −/− mice, which are protected from bleomycin-induced fibrosis. 17 Currently, it is not understood what causes the decreased expression of Cd28 (and CD3 complex) in IPF patients. Notably all four signature genes are expressed by T cells but the expression of inducible costimulator (Icos) is particularly important as it is constitutively expressed by follicular T helper cells (Th) that play a unique role in providing help to B cells to promote antibody synthesis in germinal centres. 18 Other immune biomarkers that also change in IPF patients include surfactant protein A, chemokine ligand 18 and metalloproteinase 7, intercellular adhesion molecule and interleukin 8 (IL-8), which have all been found to be highly expressed in peripheral blood mononuclear cells of IPF patients and correlate with decreased survival. [19] [20] [21] Collectively these studies indicate that activation and expansion of T cells in IPF patients can have an important influence on disease progression, and some specific biomarkers have been identified that can have prognostic value.
The cytokine response of CD4 + T cells has been examined in a number of studies of IPF patients and consensus indicates an imbalance in the transforming growth factor (TGF)β: IL-10 ratio and the presence of high levels of IL-17 in the serum of IPF patients. Immunostaining of IPF patient lung tissues revealed prominent IL-17 staining in regenerating epithelial cells. 14 The secretion of IL-10 and TGFβ is mediated primarily by CD4 + Foxp3 + T regulatory (Tregs) cells, which play a crucial role in immune homoeostasis and the maintenance of self-tolerance. 22 In addition, Tregs can migrate to non-lymphoid tissues where they appear to play a crucial role in dampening immune responses at mucosal surfaces. In addition, there is a growing appreciation that Tregs can play important roles outside of mucosal tissues such as the regulation of metabolic homoeostasis in adipose tissue and can promote the repair of skeletal muscle following damage. [23] [24] [25] Although there is no clear indication of the fate of Tregs in IPF patients, two studies have observed decreased numbers of Treg numbers in bronchoalveolar lavage fluid, blood and in lung tissue. 14, 26 In addition, Treg cells from IPF patients displayed poor suppressive function in vitro. 26 In contrast, in mouse models of bleomycininduced pulmonary fibrosis Tregs can accumulate in large numbers in the lung tissue and can exacerbate disease through their capacity to secrete TGFβ. Reilkoff et al. 27 identified a population of CD4 + Sem7a and CD4 + Sem7a + Tregs in the peripheral blood that were expanded in IPF patients, and in mice, the CD4 + Sem7a + Tregs were responsible for disease progression following bleomycin treatment.
A specific lack of Treg cells or a loss in their suppressive activity could have important implications on the maintenance of self-tolerance in humans and rodents, and can lead to the development of widespread autoimmunity. Naive CD4 + T cells if activated in the presence of TGFβ and IL-10 can differentiate to become inducible CD4 + Foxp3 + Tregs. 28, 29 Gagliani et al. 30 demonstrated that CD4 + Th17 cells could transdifferentiate in vivo into CD4 + Tregs, since Foxp3 expression induced in response to TGFβ signalling could silence RORγt expression, which is a nuclear transcription factor required for IL-17 synthesis. 31 Due to plasticity of the CD4 + repertoire, the cytokine milieu in which T cells find themselves can strongly influence their path of differentiation. Recently it was shown that a population of CD4 + IL-17 + Foxp3 + Tregs was expanded in the intestinal lamina propria of Crohn's disease patients. 32 These studies highlight that when CD4 + T cells are exposed for prolonged periods to cytokines, this can impact on their differentiation in vivo. TGF-β and IL-6 promote the differentiation of CD4 + T cells into the Th17 cell lineage in vivo, 33 while exposure to IL-10 and TGF-β promotes CD4 + Treg differentiation. 22 Therefore, the environmental cues within inflamed tissues may shape the balance of Th17 and Treg cells that arise, but which cell type dominates during an immune response will be determined by the balance between inflammatory versus tolerogenic signals. 32 A similar scenario may also play out in the lungs of IPF patients where TGF-β, IL-6, IL-17 and IL-10 are detected and it is the manner in which clonal populations of CD4 + T cells respond to the external cytokine signals emanating from damaged epithelial cells or other innate or lymphocyte cell populations that will determine the outcome of inflammation or immune homoeostasis.
ROLE OF B CELLS IN IPF
B cells are the antibody-producing cells of the adaptive immune system and follicular B cells are also capable of responding to two different forms of antigens referred to as (i) thymus T-independent or (ii) T-dependent (TD) antigens. T-independent antigens are associated with microbial-derived products such as cell wall antigens like peptidoglycan, flagellin or lipopolysaccharide or alternatively they may recognise DNA or RNA coming from microbes such as bacteria and viruses. 34 TD antigens are usually directed against exogenous proteins and these are processed by professional antigen-presenting cells such as dendritic cells to stimulate CD4 + Th cells. The antigenspecific Th cell needs to interact with a B cell of the same antigen specificity and the Th cells provide both cognate and soluble signals to direct B cells to differentiate into plasma cells that secrete antibody, and a subset of these cells differentiate into long-lasting memory cells. 18 T-independent responses are usually more rapid than TD responses, which is thought to help protect the host from blood borne life-threatening infections and are limited to low-affinity IgM responses. In contrast, TD antigens can drive isotype switching and somatic hypermutation of Ig variable genes to increase the affinity of antibodies for their antigen. Studies linking IPF to autoimmunity date back to the early-mid 1960s with several reports associating IPF with connective tissue diseases including rheumatoid arthritis. 35, 36 These studies were the first to demonstrate elevated circulating autoantibodies in patients with pulmonary fibrosis, albeit with rheumatism. Large foci of B-cell aggregates accumulate in the lung of IPF patients, but it is not known what draws these cells into the lung tissue during disease pathogenesis. 12,37 B-cell aggregates occur in a range of autoimmune diseases such as systemic lupus erythematosus, Sjogren's disease, thyroiditis, type 1 diabetes and rheumatoid arthritis. [38] [39] [40] Immune complexes formed between antibody and self-antigen can deposit in tissues to promote inflammation. In addition antibodies can mediate antibody-dependent cellular cytotoxicity, which is mediated via complement activation or via natural killer cell activity. Immune complexes have been identified in the peripheral blood, bronchoalveolar lavage fluid and lung parenchyma of IPF patients. 10, [41] [42] [43] A number of soluble factors that promote B-cell growth and differentiation are observed in the blood of IPF patients including B-cell-activating factor also known as B lymphocyte stimulator, IL-6 and IL-13. 44 The chemokine CXCL13 is important for directing migration of B cells to inflammatory foci to promote formation of TLSs. In addition, high levels of CXCL13 have been detected in the serum of patients suffering from a range of autoimmune diseases. [45] [46] [47] [48] CXCL13 was also demonstrated to be an important biomarker that was prognostic for IPF disease progression. 13 There was increased staining of CXCL13 in the lung of IPF patients and it was also detected in high levels in the plasma of IPF patients compared to patients with chronic obstructive pulmonary disease. 13 To examine the role of B cells in IPF in a mouse model of pulmonary fibrosis, O'Donoghue et al. 49 showed that Rag1 −/− mice which lacked both mature T and B cells were protected from bleomycin-induced pulmonary fibrosis. Furthermore they showed that simply eliminating the mature B-cell compartment in gp130757F;uMT −/− mice protected them from bleomycin-induced gp130/STAT3-mediated lung fibrosis. These studies all support a link between B cells and the pathogenesis of ILDs such as IPF. 49 
IPF AS AN AUTOIMMUNE DISEASE
In support of a potential autoimmune role for B-cell responses in IPF, serum analysis of autoantibody production in 48 serum samples from patients with IPF 36 reported 32 patients of 48 to have elevated non-organ-specific autoantibodies (including rheumatoid factors; DAT and ANF and complement fixing antibodies). No lung-specific autoantibodies were detected in this patient cohort. B-cell aggregates and the presence of plasma cells in lung tissue of IPF patients were noted around the same period but their role was largely ignored until more recent times. 11, 50, 51 Numerous studies have highlighted the presence of autoantibodies to self-antigens in IPF patients suggesting a breakdown in central tolerance in T and B cells to TD antigens (Table 1) .
B cells can act as professional antigen-presenting cells to memory T cells, as they can capture self-antigens, process and present peptide/major histocompatibility complex (MHC) molecules at the cell surface for recognition by the TCR on an autoreactive T cell. Several studies have identified that T cells from IPF patients can demonstrate proliferative responses to lung-derived autoantigens suggesting a breakdown in T-cell tolerance to these tissue-specific antigens. 16, 26, 43, [52] [53] [54] Feghali-Bostwick et al. demonstrated that CD4 + T cells from IPF patients responded to lung tissue antigens derived from IPF lung material, but did not respond to protein samples prepared from lung material of healthy controls. 53 This indicates that the IPF lung must elaborate self-antigens that have the potential to stimulate self-reactive T-cell responses when presented by antigen-presenting cells.
LOSS OF SELF-TOLERANCE IN IPF
The adaptive T cells of the CD4 + and CD8 + lineages express clonally restricted antigen-specific receptors. These cells are selected in the thymus to express TCRs with low-moderate affinity for the target antigen. 55, 56 Central tolerance in CD4 + and CD8 + T cells is mediated by antigen presentation via cortical epithelial cells in the thymus and is reinforced by antigen presentation in the medulla by medullary thymic epithelial cells (mTECs) and bone marrow-derived dendritic cells to ensure self-reactive lymphocytes are deleted within the thymus. [57] [58] [59] [60] Studies in mice and humans have revealed the important role for the nuclear transcription factor autoimmune regulator gene, Aire, which confers to a subset of mTECs the capacity for expression of tissue-restricted antigens (TRAs). 61, 62 Aire + mTECs are able to present a wide range of self-peptides in association with MHC molecules to induce self-tolerance to TRAs. [61] [62] [63] [64] Aire-mediated regulation of TRA expression leads to the translation of the self-proteins, which are subsequently processed by mTECs though the MHCI and MHCII pathways leading to the formation of peptide MHC complexes that are presented at the surface of mTECs and these ligands can be scanned by TCRs on thymocytes. If a TCR has high affinity for the peptide MHC complex, this will lead to clonal deletion of the autoreactive T cell. Whereas cells with low/medium affinity will be allowed to complete the differentiation and be exported from the thymus. Autoimmune polyendocrine syndrome 1 (APS-1) or autoimmune polyendocrinopathy candidiasis ectodermal dystrophy is a rare autosomal recessive monogenic autoimmune disorder caused by mutations in the AIRE gene. 65 The Aire mutation disrupts TRA expression in mTECs leading to loss of central tolerance in the thymus resulting in the export of autoreactive T cells into the peripheral circulation, which predisposes to autoimmunity. [61] [62] [63] [64] 66 Recently a second gene called Fezf2 has been discovered that can direct the expression of a further subset of TRA genes in a subset of mTECs that are different to those controlled by Aire. 67 In an effort to provide a molecular basis for the presence of autoantibodies in patients with IPF, Alimohammadi et al. 68 identified a subset of APS-1 patients that had evidence of pulmonary autoimmunity and identified the potassium channel protein, KCNRG as a putative autoantigen in these patients. In a separate study Shum et al. 69 identified a human patient with APS-1 that developed pulmonary fibrosis and identified vomeromodulin as a putative autoantigen. Shum et al. also provided the evidence that Aire −/− mice develop a pulmonary disease similar to that observed in APS-1 patients. In a follow-up study Shum et al. 70 identified a strong link between an autoimmune response to the lung-specific protein BPIFB1 (bactericidal/permeability-increasing fold-containing B1) in APS-1 patients. They found 100% of APS-1 patients with ILD had autoantibodies in the serum to BPIFB1, but it was also found to be an autoantigen in non APS-1 patients. Furthermore~15% of patients with connective tissue disease-associated ILD and 12% of IPF patients displaying autoantibodies to the antigen. 70 They found transfer of serum-containing BPIFB1 autoantibodies did not confer ILD to recipient mice with an intact immune system, but transfer of CD4 + BPIFB1 − -specific T cells to Rag1 −/− mice developed spontaneous pulmonary fibrosis and inflammation. 70 Furthermore thymic transplant from Aire −/− to immunodeficient Balb/c nude mice lead to spontaneous development of BPIFB1 autoantibodies in the blood of recipients. Thymic transplants of Aire +/ − thymi to nude mice did not yield any autoantibodies. 70 Finally they also showed that immunisation of BPIFB1 − / − mice with the BPIFB1 protein could induce autoantibodies to BPIFB1 and they went onto develop ILD similar to that observed in Aire −/− mice and IPF patients. 70 Tzouvelekis et al. 71 identified patients with combined pulmonary fibrosis and emphysema that displayed increased levels of circulating anti-nuclear antibodies in serum and they had large lymphoid aggregates within lung tissue that consisted of primarily of CD20 + B cells. Thus it appears that chronic pulmonary diseases such as IPF can be associated with a breakdown in immune tolerance and generation of autoimmunity. Table 1 provides a summary of the known autoantigens that have been described in IPF patients and those antigens highlighted in bold have been shown to be present in APS-1 patients linking it to a defect in central tolerance mediated by AIRE.
CONCLUSION
In the last 20 years, immunologists have gained greater insight into the links between the innate and adaptive immune response generated not only to pathogens but also to self-antigens in the context of autoimmunity. Susceptibility to IPF is likely to have requirements of genetic and environmental components. Genome-wide association studies have identified some key target genes and a number of these have been associated with cellular function of epithelial cells in the airways. Defects in signalling pathways that are crucial to clearing cellular debris may facilitate autoantibody formation and this may tip the scales toward disease pathogenesis. A failure to appropriately regulate the adaptive immune response could be detrimental to the host, and predispose to chronic inflammation and damage and tissue remodelling with deposition of collagen leading to fibrotic disease. Th cell differentiation is directed by the presence of cytokines and the balance between proinflammatory or immune regulatory cytokines during the period of damage to lung epithelial cells, which could favour development of autoimmunity.
The recent discovery of the role of Aire and predisposition to pulmonary fibrosis in both mice and humans provides a new and exciting breakthrough in providing a molecular mechanism to explain the breakdown in immune tolerance to lung-derived self-antigens. Although Aire mutations may only be present in a subset of IPF patients, it does provide an avenue to understand how a breakdown in T-cell tolerance may occur and how the autoreactive T and B cells may be inappropriately activated. Perhaps there are other Aire-like genes such as Fezf2, that direct TRA expression in the thymus that awaits to be discovered. Mutations in genes that direct promiscuous expression of TRAs in thymic mTECs could explain the diversity of target autoantigens that have been defined to date in IPF patients. Once the initial priming event has occurred, this can lead to the formation of memory T and B cells specific for the target autoantigens. Because of the altered costimulatory requirements of memory cells, this can prove more challenging in trying to dampen immune responses to self-antigens. Nevertheless scientists have made some significant advances in understanding the process of disease pathogenesis in IPF. Although we may still be some distance away from understanding the full pathogenesis of the disease, it has revealed some important insights that provide potential targets for immunotherapy in the future.
Future studies may need to focus on how the innate and adaptive immune responses in IPF unfold. There have been significant breakthroughs in our understanding of the diversity of innate cellular repertoire that helps to maintain immune homoeostasis in mucosal sites. The innate immune cells play a critical role in directing epithelial cell repair and maintaining the barrier function of the epithelium. The next decade should be able to provide a fertile area of research, as the genetic tools for studying disease pathogenesis are being developed and provide a valuable resource to understand how dysregulation of the immune system occurs. Although the mouse models of IPF may not accurately reflect on the inflammatory response in IPF patients, they will still prove valuable to help scientists dissect the cellular and molecular regulation of immune response in what is a complex disease.
